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REVIEW ARTICLE
For a medicine to be registered in a new country,
manufacturers are generally required to provide
substantial evidence to support the efficacy in
the claimed indication in accordance with local
regulatory standards. Substantial evidence is usu-
ally interpreted as statistically significant results
with family-wise type I error rate controlled at two-
sided 5% from at least two adequately designed
phase III confirmatory trials, or in special situa-
tions, one pivotal phase III confirmatory trial with
statistical evidence considerably stronger than 
p < 0.05 (e.g. p < 0.001).1,2
Well-designed phase III confirmatory trials
are crucial for marketing approval of a new med-
icine. However, phase III confirmatory trials are
often time-consuming and very expensive. Even
with good knowledge obtained from a series of
adequately planned phase I and II studies, there
may still be some uncertainty at the beginning of
a phase III trial with respect to design and analysis.
During the past decade, there has been increasing
interest in applying adaptive designs to the devel-
opment of medicinal products. Adaptive design is
a trial design that allows some type of prospectively
planned mid-study changes without undermin-
ing the validity and integrity of the trial. Adaptive
designs have potential utility in late-phase clinical
trials. Since some planning parameters are impre-
cisely known at the design stage, adaptive design
makes it possible to discover and rectify inappro-
priate assumptions, and maximize the chance of
success.
In this article, some methodological issues with
respect to sample size re-estimation, change in
primary endpoint, interim dropping of treatment
arms, change in statistical hypothesis, and change
in the primary analysis are discussed. Several exam-
ples of design adaptation that have been encoun-
tered by the Center for Drug Evaluation in the
past 3 years are presented.
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Methodological Issues with Adaptive
Design
The key considerations in regulatory setting for
trials using adaptive design are that statistical meth-
ods for the control of type I error should be pre-
specified; correct estimates of treatment effect and
associated confidence intervals should be available;
the maintenance of the study blinding should be
ensured; and methods for the assessment of con-
sistency of treatment effect across all design modi-
fications should be preplanned.3 To cope with
these considerations, the methodological issues
with regards to several types of anticipated design
modification are discussed here.
Sample size re-estimation
It is acknowledged that when planning a late phase
II or even a phase III confirmatory trial, uncertainty
may still exist about the parameter assumptions
used for sample size calculation. The need to re-
assess sample size in an ongoing trial for some
situations in which treatment response cannot
be reliably predicted is understandable. However,
the option of reassessing sample size based on the
results of interim analysis should be justified at
the planning stage, and the analysis method to con-
trol the type I error must be prespecified.
Studies have shown that methods for blinded
sample size reassessment based on updating a
nuisance parameter such as within-group vari-
ance or pooled event rate can properly control the
type I error.4–7 Blinded sample size re-estimations
have an added advantage in that they can be per-
formed by trial teams without use of a third
party. On the other hand, sample size reassessment
based on unmasking interim estimate of treatment
difference may inflate the type I error. Since the
integrity of the trial after observing the treatment
difference is queried, the implications of un-
masking sample size adjustment at the interim
stage need to be carefully justified. Advanced sta-
tistical methods are available to protect the type I
error when unmasking sample size recalculation
is employed.8,9 However, increasing study sam-
ple size to achieve statistical significance does
not mean that a clinically meaningful treatment
effect is still preserved.
Change in primary endpoint
The primary endpoint is the variable that is capa-
ble of providing the most clinically relevant and
convincing evidence.10 It is usually not selected
based on its ability to differentiate between treat-
ment and control, but rather to describe a relevant
clinical benefit in the treatment of the condition
under study. Basically, a change in the primary
endpoint after an interim analysis should not be
acceptable. However, in some instances, there may
be good justification for changing the primary end-
point, for example, if external information suggests
that another variable may be better suited to mea-
sure patient benefit.
Interim dropping of treatment arm(s)
The flexibility to drop treatment arm(s) at interim
analyses is highly desirable for late phase studies.
From a regulatory perspective, it may be accept-
able when the mechanism for dropping is based
on safety concerns or is completely independent
of the study primary outcome variable. Simulation
studies have shown that interim dropping of a
treatment arm based on internal data may have
an impact on the overall type I error rate.11 In parti-
cular, reallocating the unused α to the remaining
arms for comparisons after dropping an arm will
inflate the type I error rate substantially. Even
though methodologies have been developed to
control type I error rate,12–14 a two-part phase II/III
trial with an exploratory phase for dose selection
followed by a confirmatory phase, in which the
confirmatory phase has stand-alone significance,
may provide the most convincing evidence of 
efficacy and is highly recommended.
Switching between superiority and
noninferiority
The Committee for Proprietary Medicinal Products
(CPMP) Points to Consider on Switching Between Su-
periority and Non-inferiority provides comprehen-
sive discussion on this topic.15 Generally, switching
from noninferiority to superiority is straightforward
and may be feasible if the trial has been properly
designed and carried out in accordance with the
strict requirements of a noninferiority trial. For
such a design modification, analysis according to
the intention-to-treat (ITT) principle is given great-
est emphasis. Multiplicity adjustment is not nec-
essary by using the closed testing principle.16 On
the other hand, switching from superiority to
noninferiority will be more troublesome because
the noninferiority margin with respect to the
control treatment should be predefined. In this
case, superiority and noninferiority tests should
both be acceptable methods, by the local regula-
tory standards, for demonstrating the efficacy of
the test treatment. In addition, the active control
should demonstrate its usual level of efficacy and
analysis according to the ITT principle, and per
protocol (PP) analysis should provide similar
findings. Wang et al17 have indicated that when the
sample size planned for testing superiority is in-
creased to show noninferiority, it may inflate type
I error. It is generally not acceptable to change the
trial objective from superiority to noninferiority
after interim results are available. Similarly, an in-
terim change in noninferiority/equivalence mar-
gin based on the unmasking of treatment effect
will be subjected to bias and is not acceptable.
Change in primary analysis
Changes in primary analysis (including changes
in the primary efficacy population, the methods of
missing data imputation, or the statistical method)
should be avoided, even if performed before the
blinding is broken. From a regulatory perspective,
the preplanned analysis should be strictly adhered
to unless there is strong evidence to show that
prespecified analysis is inappropriate and may
lead to inappropriate inference.
Experiences of the Center for Drug
Evaluation
Over the past 3 years, the number of regulatory
applications for design modification has been
growing. These requests, either described directly
in the original protocol or through a protocol
amendment, encompass all types of adaptations.
We present several cases here to exemplify the 
regulatory considerations.
Case 1 (sample size re-estimation)
A phase III, randomized, active-controlled trial
was to be conducted in subjects with community-
acquired pneumonia of sufficient severity to 
require hospitalization and treatment with intra-
venous antibiotics for a minimum of 3 days. The
primary endpoint was clinical cure rate defined
as the ratio of the number of clinically cured sub-
jects to the total number of subjects in the clini-
cally evaluable population at the test-of-cure visit.
A total of 670 subjects were required to ensure
266 evaluable subjects in each arm. A blinded in-
terim analysis was planned when data from 70%
(372) of the clinically evaluable subjects were avail-
able. If the overall observed cure rate was < 90%,
then the sample size might be adjusted based on
the observed rates.
We accepted the adaptive trial design in this
protocol because the design modification was
preplanned and would be based on blinded 
interim analysis.
Case 2 (sample size re-estimation)
A phase III, randomized, multiple-dose, placebo-
controlled, three-parallel-group study was to be
conducted to assess the pain following total knee
arthroplasty. One hundred subjects per group
was estimated by assuming an SD of 2.2, with
90% power and a two-sided test with α = 0.05. A
non-blinded interim analysis was to be perform-
ed, when 30% of subjects were either discharged
from hospital or discontinued early before dis-
charge, to investigate the assumptions used in
the sample size estimation. The results from the
interim analysis were to be used to adjust the
sample size.
The proposed design adaptation was not ac-
cepted because of concerns over bias that resulted
from knowledge of interim observed treatment
effects. In addition, no statistical methodology
was proposed to control type I error.
Regulatory view of adaptive trial design
J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl S5
M. Wang, et al
S6 J Formos Med Assoc | 2008 • Vol 107 • No 12 Suppl
Case 3 (change in primary endpoint)
A phase III, randomized, active-controlled study
was conducted in patients with chronic stable
angina pectoris. The original planned co-primary
efficacy endpoints were “time to 1 mm ST seg-
ment depression” and “time to limiting angina”.
Two weeks after study initiation, the endpoint
was redefined as “total exercise duration at the
trough of drug activity”, and the sample size was
increased from 130 to 235 subjects per group.
The main reason for this change was to comply
with CPMP guidelines that became available at
that time.
The application was accepted because the
main reason for change was justifiable and the
time for this change was sufficiently early that
most of the data had not been collected.
Case 4 (change in primary endpoint)
The protocol was identical to that in case 2. The
primary outcome variable was defined as the
mean pain score reported by the subjects using
an 11-point rating scale (0 = no pain, 10 = worst
pain), at a time after surgery when the replaced
knee was flexed to a fixed angle by an investiga-
tor or therapist using a goniometer. The time
(48–96 hours after surgery) and the angle
(45–100°) was determined after data analyses,
for which at least 90% ITT subjects reached that
angle of flexion and the difference between the
25% quartile and the 75% quartile of pain scores
was at a maximum.
The design adaptation was not acceptable be-
cause the primary endpoint was determined after
data analyses. The blinding may not have been
maintained and the integrity of the study was
questionable.
Case 5 (interim dropping of a treatment arm)
A two-stage adaptive design had been proposed
to select the optimal dose at stage 1, and then to
demonstrate superiority in overall survival at
stage 2. Patients were to be randomized to test
treatments (7.5 mg or 15 mg) or placebo on a
1:1:1 basis. The optimal dose was to be established
in an interim analysis based on the efficacy and
safety data at 18 weeks, after enrolment of the
210th patient. After the optimal dose had been
chosen, approximately 830 patients were to be
randomly assigned to either the selected dose or
placebo at a 1:1 ratio. The primary efficacy analy-
sis was to be carried out to compare the overall
survival between the selected dose group and pla-
cebo group for patients enrolled at stage 2 only.
The design adaptation was acceptable be-
cause the final analysis, using only stage 2 data,
would have had stand-alone significance.
Case 6 (interim dropping of a treatment arm)
A double-blind, randomized, phase II/III seam-
less study was to be conducted with three treat-
ment groups (test drug 20 mg QD, 10 mg BID,
and placebo). One interim analysis was planned
to select the optimal dose at the end of the phase
II stage, when a total of 300 patients (100 per
group) had been followed for 6 months. The
O’Brien and Fleming method was chosen to con-
trol type I error rate with a significance level set
at 0.0051 for interim analysis and at 0.0415 for
final analysis. An additional 300 patients were to
be randomly assigned to either the selected dose
or placebo group at a 1:1 ratio at the phase III
stage. The final analysis was to combine data from
both stages. Superiority of the test drug (selected
dose) over placebo would be claimed if the 
two-sided p value was < 0.02075.
The design modification was acceptable because
it did not reallocate the unused α to the remaining
arm after interim dropping of a treatment arm.
Case 7 (switching from noninferiority to
superiority)
A phase III, randomized, active-controlled study
was to be conducted in subjects with uncompli-
cated pelvic inflammatory disease. The primary
efficacy endpoint was the clinical cure rate at the
test-of-cure visit. The noninferiority margin was
predefined at 15%. If the lower limit of the two-
sided 95% confidence interval of the treatment
difference (test drug minus control) was greater
than −15% for the PP population and similar
findings were observed for the ITT population,
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noninferiority of the test drug compared with ac-
tive control would be claimed. If the lower limit
for the ITT population was > 0 and similar find-
ings were observed for the PP population, then
the superiority of the test drug over active control
would be claimed.
The proposed design modification was accept-
able because it would simultaneously test nonin-
feriority and superiority using a closed testing
procedure. In addition, the study was designed
and carried out in accordance with the require-
ments of a noninferiority trial, which would use
data of higher quality in the analyses.
Case 8 (change in primary endpoint and
primary analysis)
A phase III randomized, double-blind, placebo-
controlled study was conducted in patients with
advanced breast cancer. The primary efficacy end-
point was the number of 12-week periods with
new bone complication of metastatic bone dis-
ease. Ordinal logistic regression would be em-
ployed for the primary analysis. After a protocol
amendment, the primary outcome measure was
changed into AOSR (altered ordinary standard
ratio), defined as follows:
Wilcoxon rank sum test was to be applied as the
new primary analysis. The main argument for this
design modification was that the original analysis
would ignore the total observation time and might
underestimate the number of eventful periods in
those who discontinued early. This would lead to
an inappropriate inference if the dropout rates be-
tween the two study groups were imbalanced.
The argument was deemed justifiable, and this
design modification was accepted.
Concluding Remarks
A protocol is a plan that details how a clinical
trial will be carried out and how the data will be
collected and analyzed. It is the most important
document of the trial since it ensures the ade-
quacy and validity of the clinical investigations,
in terms of their planning, operation and analysis.
Adherence to the protocol is crucial during the
conduct of a clinical trial. It ensures that the 
conclusions drawn from the trial results are 
unbiased and not misleading.
Although traditional nonadaptive designs min-
imize statistical and operational biases, adaptive
designs may reflect real clinical practice in cur-
rent clinical development. Adaptive designs have
been highly desirable for most biopharmaceuti-
cal companies in recent years. However, they are
clearly not suited to all clinical trials. From a reg-
ulatory point of view, adaptive designs should be
encouraged for phase I and II trials, for better ex-
ploration of drug information, so as to be optimally
used in the planning of phase III confirmatory
trials. When design adaptation is employed in
phase III confirmatory trials, much more careful
planning is needed than in traditional nonadap-
tive trials.18 It should be made independent of the
observed treatment effect where possible. Once un-
masking is necessary, careful consideration needs
to be given to preserve the integrity of the trial.
Moreover, the procedure of adaptations selected
should always ensure that the overall probability
of type I error rate is controlled.
It is advisable that the number of adaptations
should be limited to maintain the confirmatory
nature in late drug development. Any potential
changes to the trial and the statistical procedure
should be prespecified in the protocol. The sponsor
should consult with regulatory agencies at the pro-
tocol design stage.
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